SinoMab BioScience Bruttomarge
Was ist das Bruttomarge von SinoMab BioScience?
Bruttomarge von SinoMab BioScience Limited ist 78.59%
Was ist die Definition von Bruttomarge?
Die Bruttomarge ist die Differenz zwischen Umsatz und Kosten der verkauften Waren, dividiert durch den Umsatz und in Prozent ausgedrückt.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Bruttomarge von Unternehmen in Health Care Sektor auf HKSE im Vergleich zu SinoMab BioScience
Was macht SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Unternehmen mit bruttomarge ähnlich SinoMab BioScience
- Rua Life Sciences Plc hat Bruttomarge von 78.54%
- Acrow Formwork and Construction Services hat Bruttomarge von 78.56%
- Uniti hat Bruttomarge von 78.57%
- LifeTech Scientific hat Bruttomarge von 78.57%
- Servicenow Dl ,001 hat Bruttomarge von 78.59%
- ServiceNow Inc hat Bruttomarge von 78.59%
- SinoMab BioScience hat Bruttomarge von 78.59%
- Tera Software hat Bruttomarge von 78.59%
- i-nexus Global plc hat Bruttomarge von 78.59%
- F-Secure Oyj hat Bruttomarge von 78.60%
- Magellan hat Bruttomarge von 78.61%
- Prozone Intu Properties hat Bruttomarge von 78.63%
- Pandora AS hat Bruttomarge von 78.63%